Rafferty Asset Management Boosts Stake in ACADIA Pharmaceuticals

Investment firm increases holdings in biopharmaceutical company by over 55%

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC, an investment management firm, has increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 55.1% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). Rafferty now owns 195,031 shares of the biopharmaceutical company's stock, worth approximately $4.16 million.

Why it matters

ACADIA Pharmaceuticals is a prominent biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The increase in Rafferty's stake suggests the investment firm sees potential in ACADIA's pipeline and future growth prospects.

The details

According to the 13F filing, Rafferty Asset Management purchased an additional 69,294 shares of ACADIA Pharmaceuticals during the third quarter, bringing its total holdings to 195,031 shares. This represents approximately 0.12% of ACADIA's outstanding shares. The investment firm's increased stake in ACADIA comes as the company continues to advance its lead product, NUPLAZID, and explores new indications for the drug.

  • Rafferty Asset Management increased its stake in ACADIA Pharmaceuticals during the third quarter of 2026.

The players

Rafferty Asset Management LLC

An investment management firm that has increased its holdings in ACADIA Pharmaceuticals by 55.1% during the third quarter of 2026.

ACADIA Pharmaceuticals Inc.

A biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia.

Got photos? Submit your photos here. ›

The takeaway

Rafferty Asset Management's increased stake in ACADIA Pharmaceuticals suggests the investment firm sees potential in the company's pipeline and future growth prospects, particularly as ACADIA continues to advance its lead product, NUPLAZID, and explore new indications for the drug.